These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10931614)

  • 1. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
    Dillon WC; Eckert GJ; Dillon JC; Ritchie ME
    Catheter Cardiovasc Interv; 2000 Aug; 50(4):426-30. PubMed ID: 10931614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
    Taniuchi M; Kurz HI; Lasala JM
    Circulation; 2001 Jul; 104(5):539-43. PubMed ID: 11479250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
    Pache J; Kastrati A; Mehilli J; Gawaz M; Neumann FJ; Seyfarth M; Hall D; Braun S; Dirschinger J; Schömig A
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):436-41. PubMed ID: 11948888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
    Makoni SN
    Heart; 2001 Dec; 86(6):E18. PubMed ID: 11711483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abciximab administration and outcome after intracoronary stent implantation.
    Hasdai D; Rihal CS; Bell MR; Berger PB; Grill DE; Garratt KN; Holmes DR
    Am J Cardiol; 1998 Sep; 82(6):705-9. PubMed ID: 9761077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
    Berglund U; Nilsson L; Janzon M
    Scand Cardiovasc J; 2013 Aug; 47(4):230-5. PubMed ID: 23692139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
    Claeys MJ; Van Der Planken MG; Michiels JJ; Vertessen F; Dilling D; Bosmans JM; Vrints CJ
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):283-8. PubMed ID: 12032392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Sabaté M; Fernández C; Stranieri C; Trabetti E; Pignatti PF; Macaya C
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):89-93. PubMed ID: 15166949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab-induced thrombocytopenia.
    Griffiths C; Fisher M
    QJM; 2002 Sep; 95(9):635-6. PubMed ID: 12205341
    [No Abstract]   [Full Text] [Related]  

  • 19. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
    Chan AW; Moliterno DJ; Berger PB; Stone GW; DiBattiste PM; Yakubov SL; Sapp SK; Wolski K; Bhatt DL; Topol EJ;
    J Am Coll Cardiol; 2003 Oct; 42(7):1188-95. PubMed ID: 14522478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of abciximab readministration in coronary intervention.
    Madan M; Kereiakes DJ; Hermiller JB; Rund MM; Tudor G; Anderson L; McDonald MB; Berkowitz SD; Sketch MH; Phillips HR; Tcheng JE
    Am J Cardiol; 2000 Feb; 85(4):435-40. PubMed ID: 10728946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.